What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) – Research analysts at Lifesci Capital lifted their FY2025 earnings estimates for shares of Enliven Therapeutics in a note issued to investors on Monday, March 17th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings of ($2.54) per share for the year, up from their prior estimate of ($2.57). The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.95) per share.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million during the quarter.

Separately, BTIG Research initiated coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Trading Down 3.6 %

Shares of ELVN opened at $20.28 on Wednesday. The stock has a market cap of $990.86 million, a P/E ratio of -10.67 and a beta of 1.04. Enliven Therapeutics has a 1 year low of $14.50 and a 1 year high of $30.03. The stock’s 50-day moving average price is $21.45 and its two-hundred day moving average price is $23.80.

Insider Activity

In related news, CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $25.04, for a total value of $25,040.00. Following the sale, the chief financial officer now owns 13,000 shares of the company’s stock, valued at approximately $325,520. This trade represents a 7.14 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $21.44, for a total value of $142,940.48. Following the transaction, the chief operating officer now directly owns 323,310 shares of the company’s stock, valued at approximately $6,931,766.40. This trade represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,784 shares of company stock worth $1,092,375 over the last quarter. 29.20% of the stock is currently owned by company insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ELVN. Tower Research Capital LLC TRC boosted its holdings in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after purchasing an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Enliven Therapeutics during the 4th quarter worth about $97,000. BNP Paribas Financial Markets bought a new position in shares of Enliven Therapeutics in the 4th quarter valued at about $112,000. ExodusPoint Capital Management LP acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at about $200,000. Finally, Brevan Howard Capital Management LP bought a new stake in Enliven Therapeutics during the fourth quarter worth about $228,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.